Navigation Links
Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 23, 2007 - Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported that its lead product, Defibrotide, will be the subject of a poster presentation at the World Congress of Nephrology 2007 being held in Rio de Janeiro, Brazil from April 21-25, 2007.

On Monday, April 23, 2007, Cinara Echart, Ph.D., Manager of Biological Research Laboratory at Gentium, will present a poster entitled "Defibrotide Modulates Glucose-Induced Heparanase Expression In Endothelial Cells: A Potential Mechanism Of Anti-Diabetic Activity" (Abstract #1382).

Diabetic nephropathy is characterized by a loss of glomerular basement membrane (GBM) integrity, which is a major cause of end-stage renal failure. Heparanase plays a key role in this aberrant remodeling of the GBM and has been shown to be up-regulated by hyperglycemic conditions such as found in diabetic patients.

Discussing the results, Dr. Echart said, "Our data suggests that Defibrotide not only has an effect on the down-regulation of heparanase gene expression, but also decreases its enzymatic activity in endothelial cells. Since heparanase is a critical factor in maintaining GBM integrity and is elevated in diabetic nephropathy, it should be considered for the management of this disease."

Laura Ferro, M.D., Gentium's president and chief executive officer, said, "These preclinical results are very exciting and encourage us to pursue further studies of Defibrotide's therapeutic potential in the management of diabetic nephropathy, a chronic disease for which there are limited treatment options. Further encouraging is that these data corroborate recently reported preclinical data showing Defibrotide to suppress heparanase expression and heparanase enzymatic activity in multiple myeloma cell lines."

It has previously been reported that Defibrotide, a polydisperse oligonucleotide with anti-thrombotic, thro mbolytic, anti-ischemic and anti-angiogenic proprieties, suppressed in vitro both the expression of heparanase gene and heparanase enzymatic activity in multiple myeloma tumor cell lines. Consequently, this study addressed Defibrotide's effectiveness to regulate the expression and activity of heparanase in human microvascular endothelial cell (HMEC) and rat kidney epithelial cell lines (NRK52E) grown in hyperglycemia conditions.

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, discovery and development of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status and Fast Track Designation by the U.S. Food and Drug Administration to treat Severe Veno-occlusive disease (VOD) and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F for the year ended December 31, 2005 under the caption "Risk Factors."

Source: Gentium

Contact

Gentium, S.p.A.
Gary G. Gemignani, Chief Financial Officer
212-332-1666
ggemignani@gentium.com
or
Investor Relations Contacts:
U.S.:
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777
afields@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com
or
Italy:
Burson-Marsteller
Luca Ricci Maccarini, +39 02.721431
luca_maccarini@it.bm.com


'"/>




Related medicine technology :

1. Gentiums Defibrotide Seen as Active in Multiple Myeloma
2. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... 20, 2017  Vivify Health, the pioneer and market ... awarded a very significant patent for the advancement of ... care via digital health.  This landmark patent provides the ... further secures Vivify,s position as the leader in remote ... the first company to apply consumer mobile devices, wireless ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/25/2017)... ... 2017 , ... Vetoquinol USA® , a world-class developer ... of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. ... level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... City, UT (PRWEB) , ... April 24, 2017 , ... ... efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable energy. ... remedy provider. They look to nature to find solutions for health issues, and maintain ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The bar for ... those unreal icons inhabiting the rarified air of pop and film stardom.(1) Not to ... anyone snapping pictures: the smile. Grins now run the gamut from being encrusted with ...
Breaking Medicine News(10 mins):